In contrast, targeting VEGFR-2 with DC101 in these primary tumors may not be effective because the VEGF pathway is not an important therapeutic target in pancreatic cancer [37], or because alternative pathways may be utilized. This evidence concerns the gene KDR and familial pancreatic carcinoma.